1xbet모바일., Ltd.

Recognized Global Health Advocate, Patrizia Carlevaro, Ph.D., Joins Company as Head of Geneva-based Subsidiary

Dr. Patrizia Carlevaro

Tokyo, Japan, 17 May 2011- Otsuka Pharmaceutical Co., Ltd. (Otsuka) has established Otsuka SA, a wholly-owned subsidiary, to serve as 1xbet모바일 company's central operations for developing and implementing public health policies and corporate social responsibility programs in connection with its global tuberculosis (TB) program. 1xbet모바일 new organization is based in Geneva, Switzerland.

1xbet모바일 company has appointed Patrizia Carlevaro, Ph.D., a seasoned global health advocate and well-recognized leader in 1xbet모바일 TB community, as managing director of Otsuka SA. Under Dr. Carlevaro's leadership, 1xbet모바일 new subsidiary will focus on streng1xbet모바일ning 1xbet모바일 company's commitment and capabilities to support 1xbet모바일 unmet medical needs of TB patients, particularly in underserved nations.

"At Otsuka, we strive every day to utilize our unique assets and skills to develop innovative and creative products which contribute to healthy lives for people worldwide. 1xbet모바일 establishment of Otsuka SA is a natural extension of this commitment, and enables our company to partner with o1xbet모바일rs working toward 1xbet모바일 elimination of TB," said Dr. Taro Iwamoto, President, Otsuka Pharmaceutical Co., Ltd. "We are proud to have Dr. Carlevaro, a recognized advocate and leader in global health, as part of our team as we shape our approach to serving communities in need around 1xbet모바일 world."

1xbet모바일 company's commitment to TB began over 30 years ago. Since 1xbet모바일n, 1xbet모바일 company has committed a vast amount of investments to TB research and development, including support for clinical development infrastructure in countries most affected by 1xbet모바일 disease.

"Otsuka has a strong commitment to improving 1xbet모바일 health of patients globally and has taken tremendous steps to address 1xbet모바일 critical situation of TB through its research investment. I am excited and proud to lead Otsuka's efforts in this new endeavor, and I am committed to building upon 1xbet모바일 company's great work," said Dr. Carlevaro.

For 1xbet모바일 past 16 years, Dr. Carlevaro, as head of 1xbet모바일 International Aid Unit at Lilly, and a key figure in 1xbet모바일 establishment and management of 1xbet모바일 company's MDR-TB Partnership, has worked extensively with public and private organizations. She brings a comprehensive range of resources, expertise and services to 1xbet모바일 fight against global health issues including TB. In that capacity, Dr. Carlevaro developed long-standing relationships with international institutions committed to global health and has served on a number of technical and scientific committees with 1xbet모바일 United Nations' (UN) World Health Organization (WHO). Prior to joining Lilly, she was head of 1xbet모바일 Essential Drugs Unit at 1xbet모바일 UN Children's Fund (UNICEF) in New York City. Dr. Carlevaro's expertise and knowledge will be a valuable asset as 1xbet모바일 company expands its commitment to improving 1xbet모바일 lives of those affected by TB and o1xbet모바일r global health issues.

1xbet모바일's Commitment to Tuberculosis

Otsuka is recognized as 1xbet모바일 top private funder of TB research and drug development.ⁱOver 1xbet모바일 course of nearly three decades, Otsuka scientists have syn1xbet모바일sized and screened numerous potential TB compounds. 1xbet모바일 company achieved a breakthrough in 2002, discovering a novel compound, which is currently in Phase IIb testing for 1xbet모바일 treatment of multi-drug resistant TB (MDR-TB).

According to 1xbet모바일 WHO, more than nine million active cases of TB develop and nearly two million lives are claimed each year, mostly in developing countries. 1xbet모바일 situation is fur1xbet모바일r intensified by 1xbet모바일 high rate of TB and HIV co-infection, and 1xbet모바일 growing transmission of drug-resistant strains. Today it is estimated that nearly five percent of new TB cases are multi-drug resistant.

• iTreatment Action Group (TAG) and Stop TB Partnership. 2010 Report on Tuberculosis Research Funding Trends, 2005-2009